Furiex Pharmaceuticals, Inc. Announces that the European Commission (EC) Endorses Positive Opinion of Priligy™ for the On-Demand Treatment of Premature Ejaculation in all European Union Countries
Published: Feb 01, 2012
MORRISVILLE, N.C.--(BUSINESS WIRE)--Furiex Pharmaceuticals, Inc. (Nasdaq: FURX) today announced that the European Commission endorsed the positive opinion adopted by the Committee for Human Medicinal Products (CHMP) on October 18, 2011 for Priligy™ (dapoxetine) 30 mg and 60 mg doses. Pending national approvals, the marketing authorization for the Priligy doses can be granted in the European Union Member States where the drug has not yet been approved, and also in Norway and Iceland. The indication for Priligy approved by the EC is the on-demand treatment of premature ejaculation in men between the ages of 18 and 64.